| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.0 |
| Gross profit | 0.1 | 0.0 |
| Profit before tax | -2.7 | -2.3 |
| Net income | -2.7 | -2.3 |
| EPS (diluted, $ a share) | $-3.43 | $-3.84 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +331.4% |
|---|---|
| Gross margin | 71.1% |
10-Q filed with the SEC, NASDAQ: NXL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nexalin Technology, Inc.: key numbers
- Share price
- $1.56Close, Nov 16
- Market cap
- $1.93M
- Shares outstanding
- 1.24MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nexalin Technology, Inc.
All →Nexalin Technology Partnership with Inovanexa Medical Technologies S.A.
Nexalin Technology entered into a definitive exclusive distribution agreement with Inovanexa Medical Technologies S.A. (operating as Nexalin LATAM) to commercialize the Nexalin Sync™ neurostimulation device across seven South American countries. The 10-year agreement includes an initial 100-device program, minimum revenue thresholds to maintain exclusivity, and a requirement for the distributor to fund and establish a local manufacturing facility in Brazil after the first 30 devices are purchased.
- Counterparty
- Inovanexa Medical Technologies S.A.
- Term
- 10 years
Nexalin Technology Nasdaq/NYSE Compliance Notice
Nexalin Technology has regained compliance with Nasdaq's $1.00 minimum bid price requirement. However, the company remains under a compliance plan to meet the $2.5 million minimum stockholders' equity requirement by January 4, 2027. Failure to meet this remaining equity threshold will subject the company's common stock to delisting.
- Counterparty
- The Nasdaq Stock Market LLC
Nexalin Technology Nasdaq/NYSE Compliance Notice
Nexalin Technology received a notification from the Nasdaq Hearings Panel granting a conditional extension to regain compliance with listing standards. The company must demonstrate a minimum bid price of $1.00 for 20 consecutive trading sessions by September 28, 2026, and meet the $2.5 million stockholders' equity requirement by January 4, 2027.
- Counterparty
- Nasdaq